Diagnosing Coronary Heart Disease (CHD) with RCLS
Coronary Heart Disease (CHD) is an illness where plaque builds up inside the coronary arteries. The arteries play an important role in supplying oxygen-rich blood to the heart muscles, however, over time plaque builds up and can harden. This results in the arteries becoming narrow due to not being able to deliver enough oxygen-rich blood to the heart which causes angina or a heart attack to occur.1
BHF highlighted that Coronary Heart Disease was one of the UK’s biggest killers in 2010 resulting 46,000 premature deaths of which 68% were men.2
CHD is more likely with increasing age, particularly in men. These risk factors cannot be changed, however, there are other risk factors that can be modified such as blood cholesterol, being overweight or obese, smoking, lack of physical activity, unhealthy diet and stress.
You can prevent and control many CHD risk factors with heart-healthy changes and medication. Some lifestyles often increase the chance of developing the disease such as smoking, poor diet, adequate exercise therefore, there are many lifestyle changes to help control several CHD risk factors at the same time, such as physical activity which may reduce stress, lower your blood pressure, help control diabetes and help control your weight.3
Currently, there are four state of the art, fully functional ISO12025 accredited laboratories, located in Liverpool, London, Holywood and the Randox Science Park in Antrim giving RCLS the power to output to pharmaceutical, health and research markets.
Specialising in biomarker and multiplex testing in addition to standard safety and clinical testing, RCLS provides a full laboratory service to accelerate laboratory projects to completion. Our experienced project management teams are available to provide support and guidance from initial biomarker selection through to the design of a comprehensive results data package to deliver against your project aims and timelines.
Renowned for quality and reliability, the Rx Series and Evidence series are utilised by all RCLS Laboratories, guaranteeing real cost savings as well as highly-accurate flexible testing solutions. Furthermore, RCLS perform sample testing on numerous third-party analysers situated in our laboratories dependent upon the testing which is required by the customer.
RCLS can outsource the Cardiac Risk Prediction Array in their laboratory on the Evidence Investigator. We developed a rapid array which will allow all 19 SNPs to be genotyped simultaneously on one single sample. The RCLS team aim to save your laboratory time and money. By utilising our multiplex panels including the Cardiac Risk Prediction Array Panel, RCLS can offer labour saving, time reducing and cost-effective solutions for all your laboratory testing.
If you would like to find out more information about RCLS and what it has to offer contact firstname.lastname@example.org
In early May 2019, over 550 state employees in Egypt were referred to the Egyptian public prosecution office after being forced to take a drug test under a new law.
The Ministry of Social Solidarity announced on May 5th that 15,877 state employees had recently been drug tested, and that 555 had been referred to the Administrative Prosecution Authority (APA) for testing positive for illegal drugs.
The sudden crackdown on drug users follows the government in Egypt approving a bill in March that authorised the required drug testing of all state employees from ministerial to the local level. Alongside members of the civil service, employees working for public transportation, hospitals, and other state-run institutions must also be drug tested. Anyone who refuses to be drug tested will have their employment terminated.
The new law was brought in with explicit support from Prime Minister Moustafa Madbouli, following a deadly train crash in Cairo after which the train driver tested positive for drug use.
Egyptian law does not specify the punishment for someone who tests positive for drug use, but the director of Egypt’s Fund for Drug Control and Treatment – Amr Osman – has warned that any state bus or rail drivers testing positive for drug use face imprisonment for at least two years, and a fine of 10,000 Egyptian pounds ($582).
University students and employees will also be subject to mandatory drug testing, the education minister has announced. In this case, people who test positive will be offered “treatment” and will be sacked or expelled from the university if they refuse to comply.
Randox Toxicology offer the Evidence MultiSTAT, a fully automated immunoanalyser that, utilising Biochip Array Technology (BAT), enables on-site simultaneous detection of up to 21 drugs of abuse from a single sample. The Evidence MultiSTAT requires only a small sample volume and can generate results in under 20 minutes. The process from sample entry to results is completed in only 3 simple steps, with minimal room for human error. The MultiSTAT is designed to make set-up and analysis as quick, simple and reliable as possible.
Diabetes Week is an annual week to raise awareness of diabetes. This year, the aim is to increase the public’s understanding of diabetes 1. Diabetes mellitus (DM) is a global epidemic, increasing at an alarming rate and burdening healthcare systems 2. DM is a life-long condition characterised by the body’s inability to produce / respond to insulin resulting in the abnormal metabolism of carbohydrates and elevated blood glucose levels.
Whilst it is important to increase the public’s understanding of DM, it is imperative that clinicians and physicians are aware of the different in vitro diagnostic tests to diagnose and monitor DM. Not only is this vital, but is also important that clinicians and physicians also understand the different methodologies available when choosing the diagnostic test.
It has been highlighted in numerous clinical studies that diabetic complications may be reduced through the long-term monitoring and tight control of blood glucose levels. Both fasting plasma glucose (FPG) and glycated haemoglobin A1c (HbA1c) tests are universally accepted as reliable measurements of diabetic control. However, studies have emerged highlighting the role of fructosamine in diabetes monitoring. Whilst HbA1c provides an index of glycaemia over 2 to 3 months, fructosamine provides this index over the course of 2 to 3 weeks, enabling closer monitoring of diabetic control 1.
Drawbacks of Traditional Diabetes Tests
The FPG test measures the level of blood sugars which is used to diagnose and monitor diabetes based on insulin function. The main drawback of this test is that a hormone called glucagon, produced in the pancreas, is triggered during prolonged fasting, signalling the liver to release glucose into the bloodstream. In diabetic conditions, either the body is unable to generate enough insulin or cannot appropriately respond to insulin. Consequently, FPG levels remain high 4.
In the 1980’s, HbA1c was incorporated into clinical practice as HbA1c levels correlated well with glycaemic control over a 2 to 3-month period. The main drawback of this test is that any condition that reduces the survival rate of erythrocytes such as haemolytic anaemia will falsely lower the HbA1c test results, regardless of the assay method utilised 5.
In a diabetic patient where blood glucose levels are abnormally elevated, the concentration levels of fructosamine also increase as fructosamine is formed by a non-enzymatic Maillard reaction between glucose and amino acid residues of proteins. During this glycation process, an intermediate labile Schiff base is produced which is converted to a more stable ketoamine (fructosamine) via an Amadori rearrangement 2.
Fructosamine has been identified as an early indicator of diabetic control compared to other markers such as HbA1c. Red blood cells live for approximately 120 days, HbA1c represents the average blood glucose levels for the previous 2 to 3 months. Conversely fructosamine has a shorter lifespan, about 14 to 21 days, reflecting average blood glucose levels from the previous 2 to 3 weeks. Due to the shorter time span of fructosamine, it is also used to evaluate the effectiveness of medication changes and to monitor the treatment of gestational diabetes. The test is also particularly useful in situations where HbA1c cannot be reliably measured e.g. haemolytic anaemia, thalassemia or with genetic haemoglobin variants 5.
Fructosamine Assay Methodology
The most commonly utilised method for fructosamine testing is the colorimetric method. Whilst widely available, automated and inexpensive, the main drawback is the lack of standardisation across the different fructosamine assays 4.
Randox, on the other hand, utilise an enzymatic method, offering improved specificity and reliability compared to conventional NBT-based methods. The Randox enzymatic method does not suffer from non-specific interferences unlike existing methods which can also be time consuming and difficult to automate.
The Randox fructosamine assay is also standardised to the highest level as the Randox fructosamine calibrator and control is assigned relative to human serum glycated with 14C-glucose, which directly reflects the nature of the patient sample.
With an excellent stability of 28 days on-board the analyser, the Randox fructosamine assay is developed in a liquid ready-to-use format for convenience and ease-of-use.
Randox offer fully automated applications detailing instrument-specific settings for the convenient use of the Randox fructosamine assay on a wide range of clinical chemistry analysers.
Want to know more?
Contact us or download our diabetes brochure
Reagents Resource Hub
 Diabetes UK. Diabetes Week. [Online] 2019. [Cited: May 31, 2019.] https://www.diabetes.org.uk/get_involved/diabetes-week.
 Gounden, Verena and Jialal, Ishwarlal. Fructosamine. [Online] January 23, 2019. [Cited: April 11, 2019.] https://www.ncbi.nlm.nih.gov/books/NBK470185/.
 World Health Organization (WHO). Diabetes. [Online] October 30, 2018. [Cited: May 2, 2019.] https://www.who.int/news-room/fact-sheets/detail/diabetes.
 Manzella, Debra. The Fasting Plasma Glucose Test. very well health. [Online] November 16, 2018. [Cited: April 11, 2019.] https://www.verywellhealth.com/understanding-the-fasting-plasma-glucose-test-1087680.
 BMJ. Using haemoglobin A1c to diagnose type 2 diabetes or to identify people at high risk of diabetes. [Online] 2014. [Cited: April 11, 2019.] https://www.bmj.com/content/348/bmj.g2867/rr/695927.
What is Familial Hypercholesterolemia?
Familial Hypercholesterolemia (FH) is a genetic condition which is passed down from the parents’ genes. The British Heart Foundation has highlighted that FH is caused by a genetic mutation which means the liver is unable to remove excess ‘bad’ cholesterol (LDL), therefore, the LDL level in the blood remains high.2 Someone who suffers with FH would have high cholesterol from birth which can cause other health issues including heart and circulatory disease.
Heart UK states that more than 260,000 people in the UK may have FH. However, less than 10% of this number have been diagnosed and therefore, may not be aware of their condition.3 However, to date there are no clear symptoms if someone has FH until it is considered too late.
Familial Hypercholesterolemia (FH) symptoms
- Swollen tendons/fatty lumps on the knuckles of your hands, at the back of your ankles and knees
- Cholesterol deposits around the eye-lids (looks like pale and yellowish patches)
- Grey-white cholesterol deposits around the corneas
If untreated, about 50% of men and 30% of women with FH will develop coronary heart disease by the time they are 55. More worryingly, on average in the UK, one person a day with FH has a heart attack. About a third of people don’t survive their first heart attack, and many who do survive will have damaged hearts.
The good news is that a 2008 study part-funded by the BHF found that people with FH who are diagnosed and treated before they develop heart disease generally live as long as people who don’t have FH. That’s why it is vitally important to get diagnosed as early as possible.
How Randox Biosciences can help
Randox Biosciences offers the Familial Hypercholesterolemia (FH) Arrays I & II to help encourage early diagnosis with rapid turnaround time. This allows results to be reported within days compared with NHS waiting lists which can be substantially longer.
Our two arrays are rapid, simple and accurate which enables the simultaneous detection of 40 FH-causing mutations (20 mutations per array) within the LDLR, ApoB and PCSK9 genes.
The mutational status can be determined rapidly from a single test, with a reduced need for confirmatory testing. Genetic analysis for FH mutations also allows for more accurate diagnosis compared to lipid profiling.
Familial Hypercholesterolemia (FH) Arrays I & II:
LDLR – 38 mutations
APOB – 1 mutation
PCSK9 – 1 mutation
To find out more about the products that we offer, email us email@example.com
At Randox Testing Services, we are always trying to think of new ways to get the message across about the positive impact workplace drug & alcohol testing can have on an organisation. So, we decided to speak with one of our colleagues; Simon Tibbo, who is regularly engaging with companies about how to be proactive in minimising the risks of substance misuse.
Read below to find out what he had to say.
From your experience and knowledge, what industries are currently implementing testing programmes?
Apart from the finance industry, I’ve personally seen testing programmes within almost all business sectors, from the obvious, safety critical industries, Rail Track, Maritime, Construction, Logistics, all the way through to manufacturing firms, retail outlets, and even predominantly clerical companies. If a company has a workplace substance misuse policy and are looking to satisfactorily enforce the terms within, they will be engaged with a service provider, such as Randox, to properly support the policy.
What are, in your opinion, the barriers that companies face when trying to implement working drug & alcohol testing?
The introduction of a substance misuse policy to an already existing ‘company handbook’ can be a challenge, especially if the work-force has been established for some time. People don’t tend to like change, especially within the workplace. Unions can sometimes be unwelcoming to the idea of random testing and will often look to restrict the scope of testing or the policy itself. I’d say that each industry/company will likely meet its own barriers whilst developing and implementing a policy, and some may well be unique to the individual circumstances. Often, customers may implement an amnesty period prior to the commencement of a drug testing programme. This gives employees the opportunity to come forward and declare if they have a substance misuse issue which they can address together with their employer without sanctions.
Why has there been a delay in some companies developing workplace policies that directly relate to substance misuse?
There could be many reasons as to why a company hasn’t implemented a policy, but I’d expect somewhere near the top of that list would be either the assumption there isn’t a substance misuse issue within the business/industry, the worry that a substance misuse issue within the business/industry is highlighted by the introduction of a policy, and therefore creating more problems than its seen to be solving, or even that a company is simply unaware the solution is available and beneficial.
How important within a policy is it that a company clearly outlines what is expected of an employee, and the consequences of substance misuse?
Very! A policy needs to be clear and concise in its structure and procedures. If you aren’t explaining the terms or the consequences you could potentially end up with a problematic HR process and unresolvable tribunal cases. If an employee has sight of a straightforward policy they will know what to expect if the terms are breached, not to mention enforcing it should be equally as straightforward. It is also important to state why the policy is in place – i.e. to protect the workforce, the public and the company reputation.
Is it important to state cut-offs in substance misuse policies?
For alcohol, yes, most certainly. For drugs, not so much. An alcohol test with a home office approved breathalyser will provide an evidential result, which can be directly related to a ‘site cut-off’ (in the same manner as the existence of a road legal limit). Workplace drug testing should adhere to specific guidelines set-out by the EWDTS (European Workplace Drug Testing Society) in not just it’s procedures, but also its expected substance cut-offs. The cut-offs differ between substances so it’s not quite as straightforward. My suggestion would always be, if you feel it necessary to include drug cut-off information, refer to the EWDTS guidelines, they’re available to download on the EWDTS website if anyone needs sight, but ensure your provider is working to them and don’t go into full details, it’ll serve only to add unnecessary bulk to what should ideally be a streamlined policy.
How effective has workplace testing been in helping companies reduce the risk of drug & alcohol use?
From personal experience I can tell you, I’ve seen companies implement a policy/testing practice due to an awareness of substance misuse, only to reduce the volume of testing over time as the approach has proved successful in reducing or eradicating the specific problem. I’d say that’s a testament to implementing a random testing practice, it sends a sensible message in a fair and balanced manner, which ultimately gets results. If it’s done right, it’s going to be beneficial, even if it’s not particularly well received at its inception. Other examples where testing volume has been scaled back have led to an increase in the rates of positives demonstrating that an active testing programme is a deterrent to substance misuse.
Going forward, what industries do you see adopting a more proactive approach in use of substance misuse testing?
Likely most industries, every company has a duty of care to staff, contractors, visitors and/or the public. There will always be industries that don’t agree, don’t want to uncover issues or don’t believe they exist, but it’s the people that matter and the more that’s done to promote safety, welfare and overall good practice, the more industries will settle to the idea.
About Randox Testing Services
Randox Testing Services offer a wide range of products and services for the testing of illicit substances. We can craft customised packages to suit the needs of our customers, no matter what the industry.
Our expertise and experience working within this industry allow us to provide a range of testing solutions that will impact the risk of substance use in the workplace. With an extensive collection network and quality products, we can meet the needs of your business.
To find out more, contact us:
Phone: +44 (0) 28 9442 2413
What is syphilis?
Syphilis is caused by the bacterium Treponema pallidum. Although spread through sexual contact, it is frequently passed to an unborn child by its infected mother, where it can cause congenital syphilis resulting in high rates of stillbirth and increased risk of infant mortality.
Primary syphilis is when sores appear at the point where the bacteria entered the body. These sores can appear anywhere such as: around the opening of the urethra, penis, foreskin and anus in men; the vulva, clitoris, cervix, urethra and anus in women.
Secondary syphilis occurs when untreated sores have appeared and healed. It is still infectious and maintains its ability to be passed on.Tertiary syphilis is a progression from untreated secondary forms of the infection. Left untreated, after many years, the infection can cause serious damage to the heart, brain, eyes, internal organs and nervous system, which can ultimately lead to death.
Below are some statistics that have been published: about syphilis in recent years.
- In 2017, there were approximately 422,000 diagnoses of sexually transmitted infections (STIs) made in England, around the same number that was reported in 2016.
- There were 7,137 diagnoses of syphilis reported in 2017, a 20% increase (from 5,955) relative to the year prior and a 148% increase relative to 2008.
- The impact of STIs remains greatest in young heterosexuals 15 to 24 years; black ethnic minorities; and gay, bisexual and other MSM
- The increase in syphilis follows a 10-year trend, with 78% of diagnoses in gay, bisexual and other men who have sex with men (MSM).
How is the infection passed on?
Syphilis is passed on from one person to another through sex (vaginal, anal and oral) and also by direct skin contact with syphilis sores or rashes. Symptoms do not have to be visible for it to be passed on. It can still be transmitted before sores appear or after they have disappeared. Pregnant women can also pass syphilis onto their unborn baby.
What are the complications?
If syphilis is not treated effectively, it can spread to other parts of the body. This can result in long term complications, such as damage to the heart, brain, eyes and other organs. Ultimately, this damage can even lead to death.
Confidante avoids any embarrassing examinations, allowing you to take a test in the privacy of your own home. The Confidante test is made to be quick and easy to use, with no technical jargon, making it extremely convenient.
Confidante is now only £40 with free postage and packaging (RRP £85). Your results will be delivered discreetly via post within 7 days and will not appear on your medical record.
The month of May is devoted to myositis awareness, a muscle-wasting disease resulting in reduced muscle strength and fatigue. The term ‘myositis’ is an umbrella term referring to the “general inflammation or swelling of the muscle”. However, myositis is more often referred to as a disease involving chronic inflammation of the muscles which does not improve with rest. This condition is also known as idiopathic inflammatory myopathy (IIM) 1.
Myositis is an autoimmune disease characterised by pain, muscle weaknesses, swelling and extreme fatigue which often gradually appear. Myositis can be potentially life-threatening, especially dermatomyositis which affects the heart muscle and lungs. Whilst a rare disease, it is estimated that 75,000 Americans suffer from myositis, however, many are undiagnosed or misdiagnosed with more common autoimmune diseases. Most physicians are unfamiliar with the disease and symptoms and so the consequences of this can be catastrophic in terms of long-term physical muscle damage, disability and even death 1, 2, 3.
Table 1 reviews the different forms of myositis
Table 2 reviews complications with or due to myositis
It is vital that physicians are educated to include myositis despite it being a rare disease as it is essential that myositis patients are diagnosed quickly to ensure appropriate treatment plans are implemented.
Aldolase testing has been recognised as a marker in the differential diagnosis of muscle weakness as aldolase levels remain consistent where weakness is caused by neurological problems such as multiple sclerosis (MS). Aldolase is an enzyme specifically found in skeletal muscle and the liver. When either the muscle or liver are damaged, aldolase is released into the bloodstream 13 . A few studies support aldolase testing in the diagnosis of myositis:
1. Arthritis Research & Therapy (2012): Aldolase predicts subsequent myopathy occurrence in systemic sclerosis 14
A French monocentric 4-year study prospectively evaluated n=137 systemic sclerosis (SSc) patients without proximal muscle weakness to assess the risk of myopathy related systemic sclerosis (Myo-SSc) according to the European Neuro Muscular Centre criteria. Aldolase, creatine kinase (CK), C-reactive protein (CRP), alanine transaminase (ALT) and aspartate transaminase (AST) were evaluated.
Aldolase is a valuable diagnostic tool in the identification of SSc patients at a high risk of developing subsequent Myo-SSc. This enables clinicians to monitor at-risk patients as well as identifying Myo-SSc in its earliest stages, enabling the effective and swift implementation of an appropriate treatment plan when the muscle damage is still in a reversible stage.
2. Clinical and Experimental Rheumatology (2013): Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells 15
The in vitro analysis of the gene and protein expression levels of aldolase and CK during muscle cell differentiation.
Aldolase A is expressed in the absence of CK in undifferentiated muscle cells and in the early differentiation process. Isolated elevated serum aldolase A in myositis patients reflects preferential immune-mediated damage of early regenerative cells. Aldolase is a biomarker of damaged early regenerating muscle cells.
Myositis can be a potentially life-threatening disease when undiagnosed or misdiagnosed. Aldolase is recognised as a biomarker in the diagnosis and monitoring of myositis. Randox are one of the only in-vitro diagnostic manufacturers to offer the aldolase assay in an automated and manual biochemistry format. Not only does the Randox methodology have an excellent correlation coefficient to r=0.9917 when compared against standard methods, the Randox assay is lyophilised for enhanced stability with an excellent measuring range of 1.73 – 106U/l. Moreover, applications are available detailing instrument-specific settings for the convenient use of the Randox aldolase assay on a wide range of clinical chemistry analysers.
Want to know more?
Contact us or download our high performance & unique tests brochure
Reagents Resource Hub
Clinical Chemistry Panel
 The Myositis Association. About Myositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/.
 Kobert, Linda. Myositis, a rare muscular inflammatory disease that ofen goes undiagnosed or misdiagnosed, disproportionally impacts women of color. s.l. : The Myositis Organisation.
 Muscular Dystophy UK. Myositis. [Online] [Cited: May 6, 2019.] https://www.musculardystrophyuk.org/about-muscle-wasting-conditions/myositis/.
 The Myositis Association. Types of Myositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/types-of-myositis/.
 —. Sporadic Inclusion Body Myositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/types-of-myositis/sporadic-inclusion-body-myositis/.
 —. Dermatomyositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/types-of-myositis/dermatomyositis/.
 —. Polymyositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/types-of-myositis/polymyositis/.
 —. Necrotizing Myopathy. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/types-of-myositis/necrotizing-myopathy/.
 —. Juvenile Myositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/types-of-myositis/juvenile-myositis/.
 —. Cancer-associated myositis. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/complications/cancer-associated-myositis/.
 —. Infection. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/complications/infection/.
 —. Cardiovascular Disease. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/complications/cardiovascular-disease/.
 —. Blood Tests. [Online] [Cited: May 3, 2019.] https://www.myositis.org/about-myositis/diagnosis/blood-tests/.
 Aldolase predicts subsequent myopathy occurrrence in systemic sclerosis. Tolédano, Cécile, et al. Faubourg Saint-Antoine : Arthritis Research & Therapy, 2012.
 Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Casciola-Rosen, Livia, et al. Baltimore : Clinical and Experimental Rheumatology, 2013.
There has been an established link between disorder at football games and increasing cocaine use in society, according to Deputy Chief Constable Mark Roberts, the UK’s lead on football policing. Over the past two seasons, disorder at football matches has increased (45%), and has been linked to the increase prevalence of cocaine use inside stadiums.
According to the Home Office, 2.6% of 16 – 59 year olds took cocaine in 2017-18, up 2.4% in 2013-14. The drug in the UK is becoming cheaper, purer and more accessible than before. A senior football official said, when speaking with The Independent, that it is the “massive elephant in the room”, with police sources claiming that it is “rife” at football grounds across the country.
Football policing units carry out drug checks inside football stadiums with drug detection dogs and swabbing areas such as toilets. Arrests are made at the football grounds for drug possession. In 2017, cocaine related arrests at football grounds more than doubled from 32 to 68. These numbers may seem small, however DCC Mark Roberts says a reduction in match day policing, due to budget constraints, is the reason for these low numbers. 50% of games are either police-free (11.3%) or spotter only (39.3%).
Inspector Andy Bridgewater, the head of West Midlands’ Police football unit, believes there is a real cocaine problem stating that “there is a really strong correlation today between cocaine use and football-related violence.”
Overall disorder incidents at matches jumped 36% in 2016-17 and again last year, while cocaine-related deaths in England and Wales increased in 2017 for the sixth year in a row, from 112 in 2011 to 432 in 2017.
Using Randox Toxicology’s revolutionary Biochip Array Technology, the Evidence MultiSTAT is an automated analyser that enables detection of a wide variety of multiple drug groups and provides simultaneous on-site screening with our CE marked urine and blood panels. As minimal sample preparation is required, qualitative results can be provided in less than 20 minutes, offering an effective toxicology screen for cocaine and other drugs/drug metabolites.
Acetic Acid in winemaking
When it comes to winemaking, the acidity in wine is an important component for the quality and taste. It adds a sharpness to the flavours and is detected most readily by a prickling sensation on the sides of the tongue and a mouth-watering aftertaste.
Acetic acid is a two-carbon organic acid produced in wine during or after the fermentation period. It is the most volatile of the primary acids associated with wine and is responsible for the sour taste of vinegar.
During fermentation, activity by yeast cells naturally produces a small amount of acetic acid. If the wine is exposed to oxygen, Acetobacter bacteria will convert the ethanol into acetic acid. This process is known as the “acetification” of wine and is the primary process behind wine degradation into vinegar.
|RX misano||0.117 g/l||Conc. Of standard|
|RX Monaco||0.03 g/l||Conc. Of standard|
For more information about our food testing for winemaking please contact us at: firstname.lastname@example.org
Randox RX daytona+ (FDA) 510 (K) Clearance
Randox Laboratories a world leader in the in-vitro diagnostic industry with over 35 years’ experience is pleased to announce 510K clearance from the U.S. Food and Drug Administration for the RX daytona+ clinical chemistry analyzer. Renowned for quality and reliability, the RX series leads the way with the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, diabetes and veterinary testing. Guaranteeing real cost savings through consolidation of routine and specialized tests onto a single platform, the RX series of analyzers offers excellence in patient care, delivering unrivalled precision, accuracy and reliability.
The RX daytona+ fully automated, benchtop, clinical chemistry analyzer is capable of performing high quality testing including emergency STAT sampling and boasts a combined throughput of 450 tests per hour including ISE. The most versatile chemistry analyzer in its class, the RX daytona+ presents laboratories with a range of benefits offering optimum performance, unrivalled uptime, flexibility, efficiency and functionality.
Randox have a long history of being at the forefront of diagnostic testing and have brought to market a range of innovative and versatile clinical chemistry analyzers developed to revolutionize patient testing in a variety of laboratory types including; Clinical Laboratories, University & Research Institutes, Veterinary Laboratories and Food & Wine Laboratories. The capabilities of the RX daytona+ exceed in any laboratory setting regardless of size, boasting an array of innovative features, including a significant reduction in sample volume of just 1.5-35 µl with a sample dead volume of 150 µl for standard and 100 µl for pediatric samples.
The RX daytona+ presents excellent functionality with easy to use Windows 10 based software, minimal maintenance and advanced QC capabilities generating Levey-Jennings charts, calibration curves and QC statistics all contributing to the increased precision, accuracy and reliability the RX series is famed for. As a performance advantage, the RX daytona+ provides laboratories with the ability to consolidate a wide variety of routine and specialized tests onto a single platform with excellent correlation to gold standard methodologies. Providing laboratories globally with efficiencies in time, money, ease of use, unrivalled uptime and superior technical support, the RX daytona+ is the most advanced and versatile clinical chemistry analyzer available.
Timothy Lenz – Regional Sales Manager USA
“The RX Daytona+ receiving FDA 510K clearance will provide a much-needed addition to the US clinical laboratory market. The RX Daytona+ serves the needs of lower throughput, moderate complexity labs, while still offering many of the features found on larger floor-standing analyzers – full automation, ability to process bar-coded samples in primary tubes, variable speed paddle mixers, and dedicated sample and reagent probes, all on a versatile platform with low operating costs and maintenance requirements. The high-quality construction of the RX Daytona+ ensures an incredibly reliable platform with the lowest downtime figures in its class. The wide testing menu of the RX Daytona+ allows labs to bring additional profitable testing in-house, so that results can be returned more quickly, and diagnoses/treatment plans formulated without delay. Randox is the only company that can truly provide a single-vendor solution for clinical chemistry testing – reliable analyzers, dedicated reagents, and third-party QC materials, all from the same provider.”
About Randox Laboratories
As a world leader in the in-vitro diagnostic industry with over 35 years’ experience, Randox is leading the charge in moving from a one-size-fits-all approach towards decisions, practices and products tailored to the needs of the individual. This innovative approach to diagnostics has facilitated the development of revolutionary products designed specifically to enhance a patients’ quality of life.
Want to know more?
Contact us or visit our RX page to learn more.